AUTOLOGUS CELL THERAPY
Opexa 'eliminates major liabilities' by selling Texas facility to KBI
CDMO KBI Biopharma, Inc. has acquired the lease and assets of Opexa Therapeutics’ facility in Texas after the firm’s lead MS candidate failed Ph IIb.
Archives for February 6, 2017
CDMO Rentschler looks to highlight importance of drug formulation
Rentschler Biotechnologie has announced a strategic alliance with Leukocare through which the CDMO hopes to emphasize drug formulation as a “key success factor” in drug development.
LabCorp in talks to buy PPD for $8Bn
Unconfirmed reports suggest Laboratory Corporation of America Holdings (LabCorp) is in talks to acquire contract research organization Pharmaceutical Product Development LLC (PPD).
Banned wholesaler Europharma DK hires repackager Abacus Medicine and replaces CEO
Banned wholesaler Europharma DK has appointed a new CEO and hired Abacus Medicine to repackage and distribute drugs on its behalf.
Trump's travel restrictions will hurt cell therapy sector says ISCT
If reinstated, Donald Trump’s order restricting travel to the US would hurt the cell therapy sector according to the International Society for Cellular Therapy (ISCT).
Cambrex riding high on demand for Western innovator APIs
Limited US manufacturing capacity and a growing demand for innovator APIs will drive continued growth, says Cambrex.